The latest market report published by Acute Market Reports, Inc. “Global Preterm Birth and PROM Testing Market – Growth, Future Prospects, Competitive Analysis, 2018 – 2026,” the global preterm birth and PROM testing market is expected to reach from US$ 996.3 Mn in 2017 to US$ 1,201.2 Mn by 2026 expanding at a CAGR of 2.1% from 2018 to 2026.
Browse the full report Preterm Birth and PROM Testing Market – Growth, Future Prospects, Competitive Analysis, 2018 – 2026 report at https://www.acutemarketreports.com/report/preterm-birth-and-prom-testing-market
Gynecologist worldwide have come to a common consensus that pregnancy above the age of 35 years has led to an increasing risk for preterm birth and premature rupture of membranes (PROM). It causes high blood pressure and reduced blood flow to the placenta. The risk is high for both mother and unborn child often resulting in neonatal deaths. In April 2018, Qiagen N.V. in collaboration with Parsagen Diagnostics, Inc., got approval for PartaSure. It is considered as a breakthrough option which is cost effective and highly efficacious option over other diagnostic kits for PROM testing in symptomatic patients.
In the present scenario pelvic examination is reigning the preterm birth and PROM testing market. Physicians diagnose preliminary symptoms such as vaginal discharge, vaginal bleeding and pelvic pressure in order to confirm premature birth complications. Biomarkers are being developed as an important diagnostic kit for PROM testing owing to its inherent features such as excellent diagnostic accuracy and improved sensitivity in comparison to conventional testing methods.
North America currently holds 36% market share in the global preterm birth and PROM testing market. Rising incidence of pregnancy complications associated with preterm births and increasing maternal health awareness together drive the market growth in North America region. Domicile of major players such as CooperSurgical, Inc., Qiagen, Inc., Hologic, Inc., etc. further bolster the market growth in North America region. Europe market is currently representing 28% share owing to the stringent norms sanctioned by European Medical Agency (EMA) related to premature births and establishment of well-developed healthcare infrastructure. Asia Pacific currently holds 15% share and is set to register promising growth in the near future on account of increasing complication associated with preterm labor and proactive government initiatives to provide optimum maternal care.
Biopharmaceutical companies specializing in manufacturing preterm birth and PROM testing kits are Abbott Laboratories, Inc., Biosynex, Clinical Innovations, LLC, CooperSurgical, Inc., Hologic, Inc., IQ Products, Medixbiochemica, NX Prenatal, Inc., Qiagen N.V. and Sera Prognostics, Inc.
Key Market Movements:
- Increasing pregnancy complication associated with preterm birth and PROM worldwide
- Technological advancement of biomarkers as a diagnostic kit for diagnosing PROM complications
- Supportive regulatory environment provided by healthcare agencies throughout the globe for PROM testing kit